Download PDF
TumorDiagnostik & Therapie 2024; 45(06): 395-401
DOI: 10.1055/a-2339-2159
Thieme Onkologie aktuell

Interdisziplinäre Diagnostik und Therapie von malignen Mesotheliomen

Interdisciplinary diagnostics and therapy of malignant mesothelioma
Lea I. S. van der Linde
1   Zytopathologie, Institut für Pathologie Universität Hamburg, Hamburg, Deutschland
,
Birgit Hantzsch-Kuhn
2   Onkologie, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Deutschland (Ringgold ID: RIN9213)
,
David Ellebrecht
3   Onkologie, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Deutschland (Ringgold ID: RIN9213)
,
Florian Stellmacher
4   Hämatopathologie, Institut für Hämatopathologie, Hamburg, Deutschland
,
Lutz Welker
5   Zytopathologie, Institut für Pathologie Universität Hamburg, Hamburg, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Das asbestbedingte maligne Mesotheliom (MM) gehört in Deutschland mit ca. 1000 Neuerkrankungen pro Jahr zu den häufigen berufsbedingten Krebserkrankungen. Die Diagnose eines MM ist, sofern die entsprechenden diagnostischen Kriterien erfüllt sind, sowohl aus histologischem als auch aus zytologischem Probenmaterial mit hoher Spezifität möglich. Allerdings werden viele MM zyto-/histologisch erst in fortgeschrittenen Stadien entdeckt. Klinisch/radiologische Aspekte ergänzen die Diagnostik und ermöglichen eine interdisziplinäre Beurteilung des Tumorstadiums und individuelle Entscheidungen über die bestmöglichen Therapieoptionen für jeden einzelnen Patienten. Diagnostisch hat die videoassistierte Thorakoskopie (VATS) den höchsten Stellenwert. Die Therapieplanung orientiert sich am vorliegenden MM-Subtyp, der Tumorausbreitung und Stadium sowie dem klinischen Zustand des Patienten. Die Prognose des MM ist im Allgemeinen sehr ungünstig. Dementsprechend zielt die Standardtherapie auf eine makroskopische radikale Tumorresektion im Sinne einer Zytoreduktion im Rahmen eines geeigneten multimodalen Therapiekonzepts (Chemotherapie, Strahlentherapie, Psychoonkologie). Ziel palliativer Maßnahmen sollte v.a. die Symptomkontrolle sein. Insgesamt ist die interdisziplinäre Diagnostik und Therapie des MM entscheidend für die bestmögliche Versorgung der MM-Kranken.

Abstract

The asbestos-related malignant mesothelioma (MM) is one of the common occupational cancers in Germany with approximately 1000 new cases per year. Provided that the appropriate diagnostic criteria are fulfilled, MM can be diagnosed with high specificity from both histological and cytological specimens. However, many MM are detected cyto-/histologically only at advanced stages. Clinical/radiological aspects complement each other and enable interdisciplinary assessment of tumor stage and individualized decisions on the best possible therapeutic options. Diagnostically, video-assisted thoracoscopy (VATS) has the highest priority. Therapy planning is based on the MM subtype, tumor spread and stage, and the patientʼs clinical condition. MM has generally a very unfavorable prognosis. Accordingly, the standard therapy aims at a macroscopic radical tumor resection in terms of cytoreduction within the framework of a suitable multimodal therapy concept (chemotherapy, radiotherapy, psychooncology). The aim of palliative measures should be primarily symptom control. Overall, interdisciplinary diagnosis and therapy of MM is crucial for the best possible care of MM patients.

Schlüsselwörter

malignes Mesotheliom - Zyto-/Histologie - interdisziplinäre Diagnostik und Therapie

Keywords

malignant mesothelioma - cyto-/histology - interdisciplinary diagnosis and therapy


Publication History

Received: 16 August 2023

Accepted after revision: 30 October 2023

Article published online:
02 August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 McDonald J, McDonald A. The epidemiology of mesothelioma in historical context. Eur Respir J 1996; 9: 1932-1942 DOI: 10.1183/09031936.96.09091932. (PMID: 8880114)
    CrossrefPubMedGoogle Scholar
  • 2 Aigner C, Brüning T, Eberhardt WEE. et al. Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms – Ein Experten-Konsensuspapier [The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma – An Expert Consensus Paper]. Pneumologie 2021; 75: 776-794 DOI: 10.1055/a-1404-1562.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Neumann V, Günther S, Müller K. et al. Malignant mesothelioma – German mesothelioma register 1997–1999. Int Arch Occup Environ Health 2001; 74: 383-395 DOI: 10.3238/arztebl.2013.0319.
    CrossrefPubMedGoogle Scholar
  • 4 Delgermaa V, Takahashi K, Park E. et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011; 89: 716-724 DOI: 10.2471/BLT.11.086678.
    CrossrefPubMedGoogle Scholar
  • 5 Bianchi C, Giarelli L, Grandi G. et al. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997; 6: 162-166
    PubMedGoogle Scholar
  • 6 Milano M, Zhang H. Malignant Pleural Mesothelioma A Population-Based Study of Survival. J Thorac Oncol 2010; 5: 1841-1848 DOI: 10.1097/JTO.0b013e3181f1cf2b. (PMID: 20975379)
    CrossrefPubMedGoogle Scholar
  • 7 Scherpereel A, Opitz I, Berghmans T. et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55: 479-495 DOI: 10.1183/13993003.00953-2019. (PMID: 32451346)
    CrossrefPubMedGoogle Scholar
  • 8 Scherpereel A, Astoul P, Baas P. et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Euro Respir J 2010; 35: 479-495 DOI: 10.1183/09031936.00063109. (PMID: 19717482)
    CrossrefPubMedGoogle Scholar
  • 9 Husain AN, Colby TV, Ordóñez NG. et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 142: 89-108 DOI: 10.5858/arpa.2017-0124-RA.
    CrossrefPubMedGoogle Scholar
  • 10 Müller M. Hyaluronsäuremessung im Pleuraerguss – Diagnostischer Parameter maligner Mesotheliome. Dissertation. Universität Hamburg: Fachbereich Medizin; 2005
    Google Scholar
  • 11 Galateau-Salle F, Churg A, Roggli V. et al. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. J Thorac Oncol 2015; 11: 142-154 DOI: 10.1016/j.jtho.2015.11.005.
    CrossrefPubMedGoogle Scholar
  • 12 Colby TV. The Diagnosis of Desmoplastic Malignant Mesothelioma. Am J Clin Pathol 1998; 110: 135-136 DOI: 10.1093/ajcp/110.2.135. (PMID: 9704609)
    CrossrefPubMedGoogle Scholar
  • 13 Nicholson AG, Sauter JL, Nowak AK. et al. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 2020; 15: 29-49 DOI: 10.1016/j.jtho.2019.08.2506. (PMID: 31546041)
    CrossrefPubMedGoogle Scholar
  • 14 Travis W, Brambilla E, Nicholson A. et al. The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015; 10: 1243-1260 DOI: 10.1097/JTO.0000000000000630.
    CrossrefPubMedGoogle Scholar
  • 15 Welker L, Müller M, Holz O. et al. Cytological diagnosis of malignant mesothelioma – improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007; 450: 455-461 DOI: 10.1007/s00428-007-0375-x. (PMID: 17377812)
    CrossrefPubMedGoogle Scholar
  • 16 Biancosino C, Linde LIS van der, Sauter G. et al. Cytological Diagnostic Procedures in Malignant Mesothelioma. Adv Exp Med Biol 2022; 1374: 41-49 DOI: 10.1007/5584_2021_680. (PMID: 34787829)
    CrossrefPubMedGoogle Scholar
  • 17 WHO Reporting System for Lung Cytopathology, Ed. IAC-IARC Cytopathology. Reporting Systems. 1th Edition. Bd 1. Lyon: 2022
    Google Scholar
  • 18 Hjerpe A, Ascoli V, Bedrossian C. et al. Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma. Acta Cytologica 2015; 59: 2-16 DOI: 10.1159/000377697. (PMID: 26681974)
    CrossrefPubMedGoogle Scholar
  • 19 Rusch VW. Diffuse Malignant Mesothelioma. et al. In: Shields TW, Locicero III J, Reed CE. General Thoracic Surgery. 7th ed. Lippincott Williams & Wilkins; 2009: 847-859
    Google Scholar
  • 20 Shah R, Klotz LV, Glade J. Current Management and Future Perspective in Pleural Mesothelioma. Cancers (Basel) 2022; 14: 1044 DOI: 10.3390/cancers14041044. (PMID: 35205798)
    CrossrefPubMedGoogle Scholar
  • 21 Zhou N, Rice DC, Tsao AS. et al. Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg 2022; 113: 200-208 DOI: 10.1016/j.athoracsur.2021.04.078. (PMID: 33971174)
    CrossrefPubMedGoogle Scholar
  • 22 Srour SA, Stoner JA. Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis. J Clin Oncol 2016; 34: 8554 DOI: 10.1200/JCO.2016.34.15_suppl.8554.
    CrossrefPubMedGoogle Scholar
  • 23 Dudek AZ, Wang XF, Gu L. et al. Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). J Clin Oncol 2019; 37: 8157 DOI: 10.1200/JCO.2019.37.15_suppl.8517.
    CrossrefPubMedGoogle Scholar
  • 24 Burgers JA, Gooijer C de, Cornelissen R. et al. Switch maintenance gemcitabine after first line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19). Poster presented at: European Society for Medical Oncology. Annual Meeting; 27 September–1 October 2019, Barcelona, Spain. Ann Oncol 2019; 30 (Suppl. 05) v851-v934 DOI: 10.1093/annonc/mdz394.
    CrossrefPubMedGoogle Scholar
  • 25 Zalcman G, Mazieres J, Margery J. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405-1414 DOI: 10.1016/S0140-6736(15)01238-6. (PMID: 26719230)
    CrossrefPubMedGoogle Scholar
  • 26 Baas P, Scherpereel A, Nowak AK. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet 2021; 397: P375-P386 DOI: 10.1016/S0140-6736(20)32714-8. (PMID: 33485464)
    CrossrefPubMedGoogle Scholar
  • 27 Peters S, Scherpereel A, Cornelissen R. et al. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. Annals of Oncology 2021; 32 (Suppl. 05) S1341-S1342 DOI: 10.1016/j.annonc.2021.08.2146.
    CrossrefPubMedGoogle Scholar
  • 28 Scherpereel A, Mazieres J, Greillier L. et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019; 20: 239-253 DOI: 10.1016/S1470-2045(18)30765-4. (PMID: 30660609)
    CrossrefPubMedGoogle Scholar
  • 29 Popat S, Curioni-Fontecedro A, Dafni U. et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISEmeso trial. Ann Oncol 2020; 31: 1734-1745 DOI: 10.1016/j.annonc.2020.09.009. (PMID: 32976938)
    CrossrefPubMedGoogle Scholar
  • 30 Bayman N, Appel W, Ashcroft L. et al. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial. J Clin Oncol 2019; 37: 1200-1208
    CrossrefPubMedGoogle Scholar